ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical ...
Chonnam National University has once again solidified its international reputation as Korea's leading institution in "nano-regenerative medicine" ...
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...
The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...
Cedars-Sinai scientists have developed an experimental drug that repairs DNA and serves as a prototype for a new class of ...
As the exam dates are nearing, the anticipation and anxiety to complete the syllabus are high among students. So many ...
Precise Bio, a clinical-stage regenerative medicine company pioneering bio-printed tissues and organs with an initial focus on ophthalmology, has successfully treated the first patient with PB-001, ...
Orthopedic Research Center, Department of Orthopedic Surgery, Mashhad University of Medical Science, Mashhad 91779-48564, Iran Bone and Joint Research Laboratory, Ghaem Hospital, Mashhad University of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback